Tildipirosin: An effective antibiotic against Glaesserella parasuis from an in vitro analysis.

Autor:	Peres PR; AFK Imunotech, Passo Fundo, 99052-900, Brazil., Prigol SR; AFK Imunotech, Passo Fundo, 99052-900, Brazil., Martín CBG; Microbiology and Immunology Unit, Department of Animal Health, Faculty of Veterinary Medicine, University of León, León, 24007, Spain., Feronatod C; MSD-Merck Animal Health, Madison, 7940, USA., Suriñach MC; MSD-Merck Animal Health, Madison, 7940, USA., Kreutz LC; Laboratory of Microbiology and Advanced Immunology, Faculty of Agronomy and Veterinary Medicine, University of Passo Fundo (UPF), Passo Fundo, 99052-900, Brazil., Frandoloso R; Laboratory of Microbiology and Advanced Immunology, Faculty of Agronomy and Veterinary Medicine, University of Passo Fundo (UPF), Passo Fundo, 99052-900, Brazil.
Jazyk:	angličtina
Zdroj:	Veterinary and animal science [Vet Anim Sci] 2020 Jul 21; Vol. 10, pp. 100136. Date of Electronic Publication: 2020 Jul 21 (Print Publication: 2020).
DOI:	10.1016/j.vas.2020.100136
Abstrakt:	Tildipirosin is a latest generation macrolide that is used to battle infection diseases caused by Gram-negative bacteria. Recent studies have shown the effectiveness of this antimicrobial agent against Actinobacillus pleuropneumoniae ; however, little information is available about Glaesserella parasuis , the etiological agent of Glässer's disease. In this study, the Tildipirosin activity to 100 Brazilian clinical isolates of G. parasuis was assessed using a broth microdilution assay. A total of 90% of G. parasuis isolates were sensitive at concentrations ≤ 4 µg/mL Tildipirosin, thus showing to be efficiently controlled by the therapeutic concentration recommended for pigs. On the other hand, a total of ten isolates have shown resistance to this antibiotic, with a minimal inhibitory concentration (MIC) ≥ 8 and ≤ 16 µg/ml. Notably, our findings highly support the use of Tildipirosin for treating Glässer's disease outbreaks, and it also advises the using of MIC approach to monitor the evolution of sensitivity or resistance exhibited by G. parasuis to this molecule, as well as to adjust therapeutic doses when necessary. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. CF & MCS are employees of MSD, the company that commercializes the Tildipirosin. MSD has not influenced the writing of this article. The remain authors report no financial or personal interests with other persons and public or private organizations that can influence the results reported in this article. (© 2020 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu